ライフサイエンスコーパス: beta-lactam antibiotic

1 m or vancomycin plus 1 other antipseudomonal beta-lactam antibiotic.

2 d ceftaroline, a recently approved anti-MRSA beta-lactam antibiotic.

3 o MSSA when compared with prophylaxis with a beta-lactam antibiotic.

4 ing antibiotic resistance upon exposure to a beta-lactam antibiotic.

5 m September to November 2017 and 2) received beta-lactam antibiotic.

6 (AKI) compared with vancomycin plus 1 other beta-lactam antibiotic.

7 reat due to rapidly rising resistance toward beta-lactam antibiotics.

8 k, the mecA gene, confers resistance to many beta-lactam antibiotics.

9 h continuous versus intermittent infusion of beta-lactam antibiotics.

10 a-Lactamases enable resistance to almost all beta-lactam antibiotics.

11 tors of resistance or susceptibility against beta-lactam antibiotics.

12 splays a high susceptibility to lysozyme and beta-lactam antibiotics.

13 s organism extremely difficult to treat with beta-lactam antibiotics.

14 e bulges and lyse, resembling treatment with beta-lactam antibiotics.

15 singly widespread resistance of pathogens to beta-lactam antibiotics.

16 tamases are bacterial enzymes that hydrolyze beta-lactam antibiotics.

17 tance mechanism adopted by bacteria to fight beta-lactam antibiotics.

18 cokinetic point-prevalence study including 8 beta-lactam antibiotics.

19 ing Bla to the periplasm where it hydrolyzed beta-lactam antibiotics.

20 n-resistant Staphylococcus aureus strains to beta-lactam antibiotics.

21 eat to the use of almost all clinically used beta-lactam antibiotics.

22 r ability to act on virtually all classes of beta-lactam antibiotics.

23 -lactamases, a group of enzymes inactivating beta-lactam antibiotics.

24 toward increased activity with a variety of beta-lactam antibiotics.

25 le acylation of an active site serine by the beta-lactam antibiotics.

26 udied to determine their susceptibilities to beta-lactam antibiotics.

27 cterial dd-peptidases are the targets of the beta-lactam antibiotics.

28 g with the ability to manifest resistance to beta-lactam antibiotics.

29 ardicin biosynthesis, a family of monocyclic beta-lactam antibiotics.

30 olecule strategies to overcome resistance to beta-lactam antibiotics.

31 arrested cells and restores vulnerability to beta-lactam antibiotics.

32 nt in inactivating most of the commonly used beta-lactam antibiotics.

33 of the GdpP PDE greatly sensitized cells to beta-lactam antibiotics.

34 aureus with a central role in resistance to beta-lactam antibiotics.

35 irectly by acylation of the sensor domain by beta-lactam antibiotics.

36 yme effectively, restoring susceptibility to beta-lactam antibiotics.

37 enzyme superfamily and is the target of the beta-lactam antibiotics.

38 oteins (PBPs) covalently inactivated by four beta-lactam antibiotics.

39 le in bacterial cell division and lysis with beta-lactam antibiotics.

40 ereby conferring resistance to virtually all beta-lactam antibiotics.

41 n synthesis and is covalently inactivated by beta-lactam antibiotics.

42 l biosynthesis and are the lethal targets of beta-lactam antibiotics.

43 disposing factors for immediate reactions to beta-lactam antibiotics.

44 ause bacteria have evolved resistance to the beta-lactam antibiotics.

45 l biosynthesis and are the lethal targets of beta-lactam antibiotics.

46 er resistance to an ever-broader spectrum of beta-lactam antibiotics.

47 cture and susceptibility to cell wall-acting beta-lactam antibiotics.

48 erial cell walls and are the targets for the beta-lactam antibiotics.

49 ynthesis of peptidoglycan in the presence of beta-lactam antibiotics.

50 in-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics.

51 ecreased susceptibility in vitro to multiple beta-lactam antibiotics.

52 get to enhance the susceptibility of MRSA to beta-lactam antibiotics.

53 hreat due to their ability to inactivate all beta-lactam antibiotics.

54 re first described as inactivators of common beta-lactam antibiotics.

55 resistance, rendering bacteria resistant to beta-lactam antibiotics.

56 threaten the clinical utility of almost all beta-lactam antibiotics.

57 reactions, or hypersensitivities to multiple beta-lactam antibiotics.

58 s for L-form growth and non-lytic killing by beta-lactam antibiotics.

59 of these kinases in regulating resistance to beta-lactam antibiotics.

60 p. carotovora (Ecc), the biosynthesis of the beta-lactam antibiotic 1-carbapen-2-em-3-carboxylic acid

61 P. carotovorum ATCC39048 produces the beta-lactam antibiotic, 1-carbapen-2-em-3-carboxylic aci

62 d IV vancomycin plus 1 other antipseudomonal beta-lactam antibiotic, 157 patients (8.2%) had antibiot

63 Continuous administration of beta-lactam antibiotics achieved higher plasma antibioti

64 beta-lactam antibiotics act on bacterial cell walls and

65 Bacteria are known to evade beta-lactam antibiotic action by producing beta-lactamas

66 ould effectively inhibit PrkA and potentiate beta-lactam antibiotic activity to varying degrees.

67 e penicillin-based sulfones 1-7 to repurpose beta-lactam antibiotics activity with bacterial species

68 there was no difference in outcomes between beta-lactam antibiotic administration by continuous and

69 of these are able to rescue the activity of beta-lactam antibiotics against carbapenem-resistant Aci

70 emonstrated that 20 restored the activity of beta-lactam antibiotics against carbapenem-resistant Pse

71 lack of specificity against a broad range of beta-lactam antibiotic agents.

72 Patients with reported beta lactam antibiotic allergies (BLA) are more likely t

73 Patients with reported beta-lactam antibiotic allergies (BLAs) are more likely

74 orted BLA was associated with greater use of beta lactam antibiotic alternatives.

75 orted BLA was associated with greater use of beta-lactam antibiotic alternatives.

76 in the clinic, such as an extended-spectrum beta-lactam antibiotic amoxicillin/clavulanic acid and a

77 ed in presence of other structurally related beta-lactam antibiotics (amoxicillin, oxacillin, penicil

78 t-translational level, susceptibility to the beta lactam antibiotic ampicillin, and is necessary for

79 ions reveals weak binding events between the beta-lactam antibiotic ampicillin and the porin PorB fro

80 conjugates, hereafter Ent-Amp/Amx, where the beta-lactam antibiotics ampicillin (Amp) and amoxicillin

81 C-DAD) for simultaneous determination of the beta-lactam antibiotics, ampicillin (AMP), benzylpenicil

82 acrolide resistance, including resistance to beta-lactam antibiotics, an antibiotic class prescribed

83 of several important drug classes, including beta-lactam antibiotics and antiviral and antineoplastic

84 he main bacterial mechanism of resistance to beta-lactam antibiotics and are a significant challenge

85 -beta-lactamases (MBLs) hydrolyze almost all beta-lactam antibiotics and are unaffected by clinically

86 x from the Henry-Michaelis complex formed by beta-lactam antibiotics and CBL.

87 apes of E. coli under selection by different beta-lactam antibiotics and demonstrate that the emergen

88 heriae resistant to penicillin and all other beta-lactam antibiotics and describe a novel mechanism o

89 a-lactamases catalyze the hydrolysis of most beta-lactam antibiotics and hence represent a major clin

90 Carbapenems are the most potent beta-lactam antibiotics and key drugs for treating infec

91 fely facilitate more rapid administration of beta-lactam antibiotics and may allow for better complia

92 beta-Lactamases (BLs) able to hydrolyze beta-lactam antibiotics and more importantly the last re

93 class A beta-lactamase, are resistant to all beta-lactam antibiotics and pose a major public health t

94 two antibacterials, namely, cefadroxil (CFD, beta-lactam antibiotic) and doxycycline (DXC, tetracycli

95 acting as the first line of defense against beta-lactam antibiotics, and antibiotic stress leads to

96 actamases (MBLs) degrade a broad spectrum of beta-lactam antibiotics, and are a major disseminating s

97 ceptible bacteria in the presence of several beta-lactam antibiotics, and directly degrade the antibi

98 que selective resistance-modifying agent for beta-lactam antibiotics, and it may be further developed

99 fection in patients treated with intravenous beta-lactam antibiotics, and our findings support contin

100 to explain the resistance of some strains to beta-lactam antibiotics, and the search for the missing

101 We found that critical frontline beta-lactam antibiotics antagonize fluconazole activity.

102 a large spectrum of peptidomimetics such as beta-lactam antibiotics, antivirals, peptidase inhibitor

103 Episodes treated with a parenteral beta-lactam antibiotic appear to have a more favorable o

104 Beta-lactam antibiotics are a commonly used treatment fo

105 beta-Lactam antibiotics are among the safest and most ef

106 beta-lactam antibiotics are associated with a variety of

107 The targets of beta-lactam antibiotics are bacterial DD-peptidases that

108 Intravenous beta-lactam antibiotics are considered to confer a high

109 beta-lactam antibiotics are ineffective against Mycobact

110 beta-Lactam antibiotics are often coadministered with in

111 beta-Lactam antibiotics are one of the most important an

112 beta-Lactam antibiotics are the most commonly prescribed

113 ween development of a retinal detachment and beta-lactam antibiotics (ARR, 0.74 [95% CI, 0.35-1.57])

114 r ceftriaxone heralds the possible demise of beta-lactam antibiotics as effective treatments for gono

115 PBP2a effectively discriminates against the beta-lactam antibiotics as potential inhibitors, and in

116 Interactions of different classes of beta-lactam antibiotics, as mimics of the acyl-D-Ala-D-A

117 itional antienterococcal antibiotic and/or a beta-lactam antibiotic at any time during treatment were

118 received ceftriaxone (intraperitoneally), a beta-lactam antibiotic believed to increase GLT1 express

119 ese studies will aid in the synthesis of new beta-lactam antibiotics, beta-lactamase inhibitors, and

120 sepsis diagnosis to first-dose completion of beta-lactam antibiotics between IV push and IV piggyback

121 nB mutant exhibiting enhanced sensitivity to beta-lactam antibiotics but not to other classes of anti

122 d that these 2-AI molecules also potentiated beta-lactam antibiotics by affecting mycobacterial prote

123 with intermittent dosing, administration of beta-lactam antibiotics by continuous infusion in critic

124 aureus can display substantial resistance to beta-lactam antibiotics by enclosure within a shell comp

125 ed to play a key role in the biosynthesis of beta-lactam antibiotics by isopenicillin N-synthase (IPN

126 sis for the broad clinical resistance to the beta-lactam antibiotics by methicillin-resistant Staphyl

127 ring the minimum inhibitory concentration of beta-lactam antibiotics by up to 64-fold.

128 Class D beta-lactamases hydrolyze beta-lactam antibiotics by using an active site serine n

129 Resistance to beta-lactam antibiotics can be mediated by metallo-beta-

130 Thus, the drug resistance of GNB to beta-lactam antibiotics can be rapidly assessed.

131 use have marked effects on T-cell behavior; beta-lactam antibiotics can function as immunomodulators

132 ity can be co-regulated with production of a beta-lactam antibiotic (carbapenem carboxylate) and a li

133 beta-lactamases hydrolyze the "last resort" beta-lactam antibiotics (carbapenems) used to treat mult

134 form and covalently linked to two important beta-lactam antibiotics, carbenicillin and ceftazidime.

135 A general mechanism for the formation of a beta-lactam antibiotic-CBL acyl-enzyme complex is elicit

136 The beta-lactam antibiotic ceftazidime is one of the handful

137 Moreover, administration of the beta-lactam antibiotic ceftriaxone, which promotes synap

138 ons in synaptic contact were reversed by the beta-lactam antibiotic ceftriaxone.

139 proteins is absent in mice treated with the beta-lactam antibiotic, ceftriaxone, during cocaine with

140 eltadacA mutants are highly sensitive to the beta-lactam antibiotic cefuroxime.

141 A screen for growth on the beta-lactam antibiotic cephalexin afforded a unique p-ac

142 with vancomycin plus 1 other antipseudomonal beta-lactam antibiotic combination (adjusted odds ratio,

143 lactamases are involved in interactions with beta-lactam antibiotics connected with both antibacteria

144 uct complex crystal structures of KPC-2 with beta-lactam antibiotics containing hydrolyzed cefotaxime

145 Widespread resistance to beta-lactam antibiotics currently limits the treatment s

146 is a membrane-bound receptor/sensor for the beta-lactam antibiotics, devoid of catalytic competence

147 ted peptidoglycan cross-linking to different beta-lactam antibiotics differed as a function of its pa

148 Optimization of beta-lactam antibiotic dosing for critically ill patient

149 We aimed to determine whether beta-lactam antibiotic dosing in critically ill patients

150 ant Enterobacteriaceae are resistant to most beta-lactam antibiotics due to the production of the Kle

151 required to accommodate peptide substrate or beta-lactam antibiotics during acylation.

152 P. aeruginosa developed resistance to beta-lactam antibiotics during evolution, when grown wit

153 ed of patients prescribed oral macrolide and beta-lactam antibiotics during the study period.

154 Resistance of S. aureus strains to beta-lactam antibiotics (eg, oxacillin) depends on the p

155 We hypothesized that subtherapeutic beta-lactam antibiotic exposure, determined by the pharm

156 determine therapeutic versus subtherapeutic beta-lactam antibiotic exposure.

157 athways that have evolved to the three other beta-lactam antibiotic families: penicillin/cephalospori

158 hylaxis was administered in 1610 cases and a beta-lactam antibiotic for 20,939 cases.

159 These inhibitors compete with the beta-lactam antibiotic for the same binding site on the

160 romising agent for use in combination with a beta-lactam antibiotic for the treatment of a wide range

161 Ceftaroline, a recently approved beta-lactam antibiotic for treatment of infections by me

162 enes has remained universally susceptible to beta-lactam antibiotics for 70 years.

163 Combining standard therapy with a beta-lactam antibiotic has been associated with reduced

164 m by which class A beta-lactamases hydrolyze beta-lactam antibiotics has been the subject of intensiv

165 Resistance to extended-spectrum beta-lactam antibiotics has led to a greater reliance up

166 with significantly reduced susceptibility to beta-lactam antibiotics have been recently described.

167 beta-Lactam antibiotics have been used effectively over

168 The beta-lactam antibiotics have long been a cornerstone for

169 In the 80 years since their discovery the beta-lactam antibiotics have progressed through structur

170 kinetic-pharmacodynamic assessments indicate Beta-lactam antibiotics have time-dependent killing, var

171 In S. aureus not exposed to beta-lactam antibiotics (i.e. not acylated by antibiotic

172 r conditions of induction of resistance to a beta-lactam antibiotic identified two signaling muropept

173 tified that reversed intrinsic resistance to beta-lactam antibiotics in a manner distinct from beta-l

174 the promise of such a biosensor to determine beta-lactam antibiotics in aqueous solutions by using am

175 amases are enzymes that confer resistance to beta-lactam antibiotics in bacteria, and there is a crit

176 g continuous versus intermittent infusion of beta-lactam antibiotics in critically ill patients with

177 Resistance to beta-lactam antibiotics in Gram-negative bacteria is com

178 e, the pauA2 mutant became more sensitive to beta-lactam antibiotics in human serum.

179 epair and the manifestation of resistance to beta-lactam antibiotics in many Enterobacteriaceae and P

180 d one compound which selectively potentiates beta-lactam antibiotics in methicillin-resistant S. aure

181 ed to selectively potentiate the activity of beta-lactam antibiotics in multidrug-resistant methicill

182 responsible for the intrinsic resistance to beta-lactam antibiotics in Mycobacterium tuberculosis.

183 inding protein 2X (PBP2X), a major target of beta-lactam antibiotics in pathogenic bacteria.

184 ions of which afford inducible resistance to beta-lactam antibiotics in S. aureus.

185 is the first one capable of determining nine beta-lactam antibiotics in samples of Manchega ewe milk.

186 encoding resistance to methicillin and other beta-lactam antibiotics in staphylococci, mecA, is carri

187 Staphylococcus aureus senses the presence of beta-lactam antibiotics in the milieu and transduces the

188 Staphylococcus aureus senses the presence of beta-lactam antibiotics in the milieu and transduces the

189 Thus, beta-lactam antibiotics in wide clinical use have marked

190 ones displayed additional reactivity against beta-lactam antibiotics including oxacillin, cloxacillin

191 Various conventional beta-lactam antibiotics, including penicillin-G, amoxici

192 munity settings by deactivating conventional beta-lactam antibiotics, including penicillins, cephalos

193 Beta-lactam antibiotics inhibit penicillin binding prote

194 Acylation of the sensor domain of BlaR1 by beta-lactam antibiotics initiates signal transduction to

195 r the introduction of this second generation beta-lactam antibiotic into clinical practice.

196 The inability to contain MRSA infection with beta-lactam antibiotics is a continuing public health co

197 fore deciding not to use penicillin or other beta-lactam antibiotics is an important tool for antimic

198 Reported allergy to beta-lactam antibiotics is common and often leads to unn

199 The use of beta-lactam antibiotics is compromised by resistance, wh

200 hat their capacity to increase resistance to beta-lactam antibiotics is dependent on the presence of

201 bility of most Bacillus anthracis strains to beta-lactam antibiotics is intriguing considering that t

202 The carbapenem class of beta-lactam antibiotics is known for its remarkable pote

203 MRSA resistance to beta-lactam antibiotics is mediated by two divergons tha

204 The target of beta-lactam antibiotics is the D,D-transpeptidase activi

205 primary contributor to its ability to resist beta-lactam antibiotics is the expression, following det

206 , the most common cause of resistance to the beta-lactam antibiotics is the production of beta-lactam

207 The efficacy of beta-lactam antibiotics is threatened by the emergence a

208 An important mechanism of resistance to beta-lactam antibiotics is via their beta-lactamase-cata

209 fer resistance to almost all clinically used beta-lactam antibiotics, its presence within an easily t

210 withdrawal, we tested whether ceftriaxone, a beta-lactam antibiotic known to increase the expression

211 (CPP), we determined whether ceftriaxone, a beta-lactam antibiotic known to increase the expression

212 eus (MRSA), which is resistant to nearly all beta-lactam antibiotics, limiting treatment options.

213 ideromycins utilizing the carbacephalosporin beta-lactam antibiotic loracarbef and the fluoroquinolon

214 The high sensitivity of M. luteus to beta-lactam antibiotics may result from the presence of

215 , containing the gene encoding resistance to beta-lactam antibiotics (mecA), into its C terminus.

216 Resistance to beta-lactam antibiotics mediated by metallo-beta-lactama

217 Recent work has suggested that beta-lactam antibiotics might directly affect eukaryotic

218 Tipper-Strominger hypothesis stipulates that beta-lactam antibiotics mimic the acyl-D-Ala-D-Ala moiet

219 agnostic evaluation of allergic reactions to beta-lactam antibiotics, mimicking real-life situations,

220 We considered two beta-lactam antibiotics, namely, cephalothin and aztreon

221 ng labor and delivery, common etiologies are beta-lactam antibiotics, natural rubber latex, and other

222 espread advantage across beta-lactam and non beta-lactam antibiotics, non-antibiotic drugs and even d

223 g in opening of the active site, whereby the beta-lactam antibiotic now is enabled to bind to the act

224 iating evidence for the molecular mimicry by beta-lactam antibiotics of the peptidoglycan acyl-D-Ala-

225 ere, we studied the effects of commonly used beta-lactam antibiotics on rodent and human T cells in v

226 ng of pharmaceutical dosage forms containing beta lactam antibiotics or combinations of the four firs

227 a an active process and was inhibited by the beta-lactam antibiotic oxacillin, which slowed inactivat

228 enicillin-binding protein poorly acylated by beta-lactam antibiotics, PBP2a.

229 genum is the main industrial producer of the beta-lactam antibiotic penicillin, the most commonly use

230 increased resistance against seven different beta-lactam antibiotics (penicillin G, ampicillin, cepha

231 A major mechanism of bacterial resistance to beta-lactam antibiotics (penicillins, cephalosporins, ca

232 erant and hypersensitive patients taking the beta-lactam antibiotic piperacillin and the threshold re

233 ld include a prolonged course of intravenous beta-lactam antibiotic plus metronidazole.

234 every new user of an oral fluoroquinolone or beta-lactam antibiotic prescription with at least 24 mon

235 tration, while treatment with ceftriaxone, a beta-lactam antibiotic previously shown to increase GLT1

236 o sub-lethal concentrations of quinolone and beta-lactam antibiotics primarily through proteins that

237 imitation, a high-quality genome sequence of beta-lactam antibiotic-producing Streptomyces clavuliger

238 High-dose drugs, especially beta-lactam antibiotics, RCM and clindamycin, are common

239 However, beta-lactam antibiotics remain the best treatment choice

240 beta-lactam antibiotics represent one of the most common

241 the specific detection and quantification of beta-lactam antibiotics residues in milk, which was acco

242 omal AmpC beta-lactamase is a major cause of beta-lactam antibiotic resistance in the Gram-negative b

243 colocalize Bla into the periplasm and confer beta-lactam antibiotic resistance to cells.

244 Here we show that the protein conferring beta-lactam antibiotic resistance, penicillin-binding pr

245 ns are a common route to clinically relevant beta-lactam antibiotic resistance.

246 a membrane-bound protein marker that confers beta-lactam antibiotic resistance.

247 a cell wall, or blocking its synthesis with beta-lactam antibiotics, results in an increased flux th

248 Our data indicate that beta-lactam antibiotics should be included in the treatm

249 Combinations of beta-lactam antibiotics show promise in overcoming MDR P

250 m molecule, opens an unprecedented realm for beta-lactam antibiotic structure-based design.

251 served among those individuals who receive a beta-lactam antibiotic such as cefazolin.

252 of its infection has been accomplished using beta-lactam antibiotics such as the penicillins and the

253 tructurally complex members of this class of beta-lactam antibiotics, such as thienamycin.

254 ) to combinations of avibactam and different beta-lactam antibiotics, suggest that it may be possible

255 sted the hypothesis that upon treatment with beta-lactam antibiotics, susceptible Enterobacteriaceae

256 The beta-lactam antibiotic temocillin (6-alpha-methoxy-ticar

257 ant was also significantly more sensitive to beta-lactam antibiotics than Schu S4.

258 Lactivicin (LTV) is a natural non-beta-lactam antibiotic that inhibits penicillin-binding

259 Metampicillin is a beta-lactam antibiotic that is prepared by the reaction

260 Penicillin refers to a group of beta-lactam antibiotics that are the first-line treatmen

261 can resensitize several MRSA strains to the beta-lactam antibiotics that are widely used in the clin

262 the phenotypic resistance profile, including beta-lactam antibiotics that were used to treat ESBL-pos

263 cis contains the genes necessary for sensing beta-lactam antibiotics, the B. anthracis sigP and rsiP

264 e herein the discovery of a new class of non-beta-lactam antibiotics, the oxadiazoles, which inhibit

265 In bacteria susceptible to beta-lactam antibiotics, the transpeptidase activity of

266 In the presence of beta-lactam antibiotics these altered cell-wall segments

267 n enzyme involved in the biosynthesis of the beta-lactam antibiotic thienamycin.

268 erfamily involved in the biosynthesis of the beta-lactam antibiotic thienamycin.

269 ogical efforts to preserve the future of the beta-lactam antibiotics through a better understanding o

270 ms of resistance, and the development of new beta-lactam antibiotics through side-chain modification

271 Serine active-site beta-lactamases hydrolyze beta-lactam antibiotics through the formation of a coval

272 herapy with vancomycin and 1 antipseudomonal beta-lactam antibiotic throughout the first week of hosp

273 sion of beta-lactamase in the absence of any beta-lactam antibiotic, thus indicating that they serve

274 The ability of an anti-MRSA beta-lactam antibiotic to stimulate allosteric opening o

275 art responsible for the decreased ability of beta-lactam antibiotics to combat infections.

276 at was designed to be given with intravenous beta-lactam antibiotics to degrade excess antibiotics in

277 (CLSI) lowered the MIC breakpoints for many beta-lactam antibiotics to enhance detection of known re

278 LIs) can be administered in combination with beta-lactam antibiotics to negate the action of the beta

279 beta-Lactamases hydrolyze beta-lactam antibiotics to provide drug resistance to ba

280 cs, angiotensin II receptor antagonists, and beta-lactam antibiotics) to inhibit OAT1 expressed in Ch

281 actam and zidebactam) potentiate activity of beta-lactam antibiotics, to various extents, against car

282 demonstrate that bacterial persisters, under beta-lactam antibiotic treatment, show less cytoplasmic

283 exes formed by l,d-transpeptidases with some beta-lactam antibiotics undergo non-hydrolytic fragmenta

284 l resistance (AMR) facilitated by widespread beta-lactam antibiotic use.

285 l disturbance, severe neutropenia, and prior beta-lactam antibiotic use.

286 ity in the nanomolar range for ampicillin, a beta-lactam antibiotic, used as biorecognition elements

287 The paper card can also detect substandard beta lactam antibiotics using an iodometric back-titrati

288 from sepsis diagnosis to administration of a beta-lactam antibiotic was 48 minutes (19-96 min) versus

289 acterized by low level activity with several beta-lactam antibiotics was constructed and employed as

290 The T-cell protein that covalently bound beta-lactam antibiotics was found to be albumin.

291 Additionally, resistance to non-beta-lactam antibiotics was significantly associated wit

292 roteins (PBPs), which are proven targets for beta-lactam antibiotics, we developed a high-throughput

293 Proteins related to the degradation of beta-lactam antibiotics were abundant in EVs released fr

294 occus aureus upon exposure to four different beta-lactam antibiotics were investigated as a function

295 eported penicillin allergies who receive non-beta-lactam antibiotics when compared to their non-penic

296 rigger enables synergy between two different beta-lactam antibiotics, wherein occupancy at the allost

297 taphylococcus aureus (MRSA) are resistant to beta-lactam antibiotics, which inhibit bacterial cell wa

298 with increased use of broad-spectrum and non-beta-lactam antibiotics, which results in increased adve

299 y (53.1%) could have received an alternative beta-lactam antibiotic with in vitro susceptibility to t

300 sh group was less likely to fail the goal of beta-lactam antibiotics within 1 hour (44.6% vs 57.3%; o